{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:54:37Z","timestamp":1792155277648,"version":"4.4.0"},"reference-count":130,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Bladder cancer is a highly heterogeneous malignant tumor of the urinary system with high recurrence rates, posing significant challenges in its diagnosis and treatment. Advances in multi-omics research have elucidated the molecular mechanisms underlying the pathogenesis and progression of bladder cancer, including driver gene mutations (e.g., FGFR3, TP53\/RB1), dysregulation of signaling pathways (such as PI3K\/AKT\/mTOR and RAS-MAPK), epigenetic alterations, non-coding RNA networks, tumor microenvironment remodeling, and metabolic reprogramming. This review systematically summarizes recent progress in translational research bridging molecular mechanisms to breakthroughs in precision therapy, covering the clinical applications and challenges of FGFR inhibitors, immune checkpoint inhibitors, antibody-drug conjugates, and gene therapies. Translational efforts are increasingly relying on molecular subtyping to develop subtype-specific treatment strategies. Although significant advances have been made in precision therapy for bladder cancer, critical research gaps remain, including tumor heterogeneity, therapy resistance, and insufficient validation of biomarkers. Future research directions emphasize the potential of liquid biopsy for non-invasive diagnosis and dynamic monitoring, rational combination therapies, multi-omics data integration, and artificial intelligence in advancing personalized treatment, providing a systematic and forward-looking perspective on precision medicine in bladder cancer.<\/jats:p>","DOI":"10.3389\/fonc.2025.1670574","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T05:12:43Z","timestamp":1765170763000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Jinjie","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunbin","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"Van Der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrc.2017.102","article-title":"An evolutionary perspective on field cancerization","volume":"18","author":"Curtius","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.eururo.2006.11.025","article-title":"On the origin of syn- and metachronous urothelial carcinomas","volume":"51","author":"H\u00f6glund","year":"2007","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199203123261104","article-title":"Clonal origin of bladder cancer","volume":"326","author":"Sidransky","year":"1992","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-16-0436","article-title":"Paired exome analysis reveals clonal evolution and potential therapeutic targets in urothelial carcinoma","volume":"76","author":"Lamy","year":"2016","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2023.07.014","article-title":"Field cancerization is associated with tumor development, T-cell exhaustion, and clinical outcomes in bladder cancer","volume":"85","author":"Strandgaard","year":"2024","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: Treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12602","article-title":"FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies","volume":"44","author":"Noeraparast","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2025.04.005","article-title":"Clinical and genomic landscape of FGFR3 alterations across different stages of urothelial cancer","volume":"77","author":"Haas","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-32","article-title":"Clinical significance of altered nm23-H1, EGFR, RB and p53 expression in bilharzial bladder cancer","volume":"9","author":"Khaled","year":"2009","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12685","article-title":"Alterations of p53 and rb pathways are associated with high proliferation in bladder urothelial carcinomas","volume":"38","author":"Goussia","year":"2018","journal-title":"Anticancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.4111\/icu.20240250","article-title":"Dasatinib induces apoptosis and autophagy by suppressing the PI3K\/Akt\/mTOR pathway in bladder cancer cells","volume":"65","author":"Ho","year":"2024","journal-title":"Investig Clin Urol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41698-025-00989-4","article-title":"G\u03b1i3: a crucial biomarker and therapeutic target in bladder cancer","volume":"9","author":"Zhang","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.02.014","article-title":"Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators","volume":"11","author":"Qiu","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2024.101280","article-title":"Hippo signaling modulation and its biological implications in urological Malignancies","volume":"98","author":"Tong","year":"2024","journal-title":"Mol Aspects Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/jci171164","article-title":"YAP1 induces bladder cancer progression and promotes immune evasion through IL-6\/STAT3 pathway and CXCL deregulation","volume":"135","author":"Sadhukhan","year":"2024","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.925278","article-title":"Clinical potential of the Hippo-YAP pathway in bladder cancer","volume":"12","author":"Cheng","year":"2022","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.AC120.014698","article-title":"Naturally occurring hotspot cancer mutations in G\u03b1(13) promote oncogenic signaling","volume":"295","author":"Maziarz","year":"2020","journal-title":"J Biol Chem"},{"key":"B25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/nyas.14358","article-title":"Tissue stiffness contributes to YAP activation in bladder cancer patients undergoing transurethral resection","volume":"1473","author":"Ghasemi","year":"2020","journal-title":"Ann N Y Acad Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2017.12.005","article-title":"Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer","volume":"115","author":"Ciamporcero","year":"2018","journal-title":"Free Radic Biol Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"6160","DOI":"10.1038\/s41467-021-26421-6","article-title":"Pparg signaling controls bladder cancer subtype and immune exclusion","volume":"12","author":"Tate","year":"2021","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6538","DOI":"10.1038\/s41467-024-50678-2","article-title":"Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer","volume":"15","author":"Plumber","year":"2024","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41467-018-08157-y","article-title":"Recurrent activating mutations of PPAR\u03b3 associated with luminal bladder tumors","volume":"10","author":"Rochel","year":"2019","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41392-023-01559-5","article-title":"Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies","volume":"8","author":"Jing","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.07.166","article-title":"miR-7-5p acts as a tumor suppressor in bladder cancer by regulating the hedgehog pathway factor Gli3","volume":"503","author":"Li","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.11.006","article-title":"Non-canonical GLI1\/2 activation by PI3K\/AKT signaling in renal cell carcinoma: A novel potential therapeutic target","volume":"370","author":"Zhou","year":"2016","journal-title":"Cancer Lett"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0041-5","article-title":"Sonic hedgehog signaling may promote invasion and metastasis of oral squamous cell carcinoma by activating MMP-9 and E-cadherin expression","volume":"31","author":"Fan","year":"2014","journal-title":"Med Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01439-z","article-title":"The Notch signaling pathway: a potential target for cancer immunotherapy","volume":"16","author":"Li","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07955-3","article-title":"The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution","volume":"635","author":"Nguyen","year":"2024","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29030117","article-title":"Urothelial bladder carcinomas with high tumor mutation burden have a better prognosis and targetable molecular defects beyond immunotherapies","volume":"29","author":"Voutsadakis","year":"2022","journal-title":"Curr Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cell.2019.02.012","article-title":"Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis","volume":"176","author":"Petljak","year":"2019","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41467-017-01358-x","article-title":"Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis","volume":"8","author":"Letouz\u00e9","year":"2017","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41420-024-01883-x","article-title":"Molecular profiling of a bladder cancer with very high tumour mutational burden","volume":"10","author":"Scimeca","year":"2024","journal-title":"Cell Death Discov"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.05.024","article-title":"Diagnostic test accuracy of urinary DNA methylation-based biomarkers for the detection of primary and recurrent bladder cancer: A systematic review and meta-analysis","volume":"10","author":"Silva-Ferreira","year":"2024","journal-title":"Eur Urol Focus"},{"key":"B47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/cbm-160673","article-title":"Detection of bladder cancer in urine sediments by a hypermethylation panel of selected tumor suppressor genes","volume":"18","author":"Pietrusi\u0144ski","year":"2017","journal-title":"Cancer biomark"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3390\/ijms20061291","article-title":"Revisiting histone deacetylases in human tumorigenesis: the paradigm of urothelial bladder cancer","volume":"20","author":"Giannopoulou","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.166877","article-title":"TET-TDG active DNA demethylation at cpG and non-cpG sites","volume":"433","author":"Denizio","year":"2021","journal-title":"J Mol Biol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2008.05.012","article-title":"UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion","volume":"582","author":"Wang","year":"2008","journal-title":"FEBS Lett"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2019.152772","article-title":"Long noncoding RNA GAS6-AS2 sponges microRNA-493, thereby enhancing the Malignant characteristics of breast cancer cells via upregulation of FUT4","volume":"216","author":"Li","year":"2020","journal-title":"Pathol Res Pract"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1172\/jci96218","article-title":"Long noncoding RNA BLACAT2 promotes bladder cancer-associated lymphangiogenesis and lymphatic metastasis","volume":"128","author":"He","year":"2018","journal-title":"J Clin Invest"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1038\/s41467-018-06152-x","article-title":"LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment","volume":"9","author":"Chen","year":"2018","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1172\/jci130892","article-title":"Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"key":"B56","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s40291-019-00410-4","article-title":"MicroRNAs: key players in bladder cancer","volume":"23","author":"Li","year":"2019","journal-title":"Mol Diagn Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.4984","article-title":"miR\u221221 inhibits autophagy and promotes Malignant development in the bladder cancer T24 cell line","volume":"56","author":"Zhang","year":"2020","journal-title":"Int J Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3540","article-title":"Expression and clinical significance of microRNA-21, maspin and vascular endothelial growth factor-C in bladder cancer","volume":"10","author":"Zhang","year":"2015","journal-title":"Oncol Lett"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3689","article-title":"miR-128 downregulation promotes growth and metastasis of bladder cancer cells and involves VEGF-C upregulation","volume":"10","author":"Zhou","year":"2015","journal-title":"Oncol Lett"},{"key":"B60","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12885-015-1110-7","article-title":"MiRNA-141 and miRNA-200b are closely related to invasive ability and considered as decision-making biomarkers for the extent of PLND during cystectomy","volume":"15","author":"Liu","year":"2015","journal-title":"BMC Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-024-00627-0","article-title":"Hsa_circ_0000520 suppresses vasculogenic mimicry formation and metastasis in bladder cancer through Lin28a\/PTEN\/PI3K signaling","volume":"29","author":"Zhang","year":"2024","journal-title":"Cell Mol Biol Lett"},{"key":"B62","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"B63","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ucl.2019.09.008","article-title":"Heated intravesical chemotherapy: biology and clinical utility","volume":"47","author":"Tan","year":"2020","journal-title":"Urol Clin North Am"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.05.002","article-title":"PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis","volume":"76","author":"Ghate","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-020-00396-3","article-title":"CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling","volume":"22","author":"Xiu","year":"2021","journal-title":"BMC Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26123","article-title":"Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer","volume":"130","author":"Eruslanov","year":"2012","journal-title":"Int J Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003416","article-title":"Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer","volume":"10","author":"Xu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2016.08.002","article-title":"CXCL1-mediated interaction of cancer cells with tumor-associated macrophages and cancer-associated fibroblasts promotes tumor progression in human bladder cancer","volume":"18","author":"Miyake","year":"2016","journal-title":"Neoplasia"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.01.017","article-title":"A phase 1 trial of durvalumab in combination with bacillus calmette-guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: the hoosier cancer research network GU16\u2013243 ADAPT-BLADDER study","volume":"83","author":"Hahn","year":"2023","journal-title":"Eur Urol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14078","article-title":"Tumor-associated macrophages promote bladder tumor growth through PI3K\/AKT signal induced by collagen","volume":"110","author":"Qiu","year":"2019","journal-title":"Cancer Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.04.006","article-title":"Differences between CAFs and their paired NCF from adjacent colonic mucosa reveal functional heterogeneity of CAFs, providing prognostic information","volume":"8","author":"Berdiel-Acer","year":"2014","journal-title":"Mol Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13046-017-0495-3","article-title":"Cancer cells increase endothelial cell tube formation and survival by activating the PI3K\/Akt signalling pathway","volume":"36","author":"Cheng","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1041588","article-title":"Targeting the VEGF pathway in metastatic bladder cancer","volume":"24","author":"Mazzola","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"B74","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/cancers13010131","article-title":"Immune checkpoint inhibitors for the treatment of bladder cancer","volume":"13","author":"Lopez-Beltran","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nature06734","article-title":"The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth","volume":"452","author":"Christofk","year":"2008","journal-title":"Nature"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.07.021","article-title":"Precise targeting of lipid metabolism in the era of immuno-oncology and the latest advances in nano-based drug delivery systems for cancer therapy","volume":"14","author":"Zhang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.108223","article-title":"Development of a prognostic model for muscle-invasive bladder cancer using glutamine metabolism","volume":"171","author":"Hao","year":"2024","journal-title":"Comput Biol Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1546160","article-title":"Histological and immunohistochemical approaches to molecular subtyping in muscle-invasive bladder cancer","volume":"15","author":"Attanasio","year":"2025","journal-title":"Front Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.05.037","article-title":"Proteogenomic characterization of bladder cancer reveals sensitivity to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand in FGFR3-mutated tumors","volume":"85","author":"Groeneveld","year":"2024","journal-title":"Eur Urol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/cancers10040100","article-title":"Bladder cancer: new insights into its molecular pathology","volume":"10","author":"Inamura","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2024.08.005","article-title":"A versatile and upgraded version of the lundTax classification algorithm applied to independent cohorts","volume":"26","author":"Cotillas","year":"2024","journal-title":"J Mol Diagn"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.003","article-title":"Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial","volume":"35","author":"Siefker-Radtke","year":"2024","journal-title":"Ann Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-01009-4","article-title":"Targeting the FGFR pathway in urothelial carcinoma: the future is now","volume":"23","author":"Peng","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.794","article-title":"Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF\/FGFR genomic alterations: final results from FIGHT-201","volume":"35","author":"Necchi","year":"2024","journal-title":"Ann Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12885-018-4059-5","article-title":"Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer","volume":"18","author":"Pulido","year":"2018","journal-title":"BMC Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0216-x","article-title":"A phase II trial of temsirolimus in second-line metastatic urothelial cancer","volume":"29","author":"Gerullis","year":"2012","journal-title":"Med Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.31.6067","article-title":"Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75","volume":"29","author":"Hahn","year":"2011","journal-title":"J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"Von Der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur Urol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.Ccr-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1021\/acsptsci.4c00663","article-title":"A comprehensive review of current approaches in bladder cancer treatment","volume":"8","author":"Kumbham","year":"2025","journal-title":"ACS Pharmacol Transl Sci"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000002662","article-title":"Global clinical trial landscape and therapeutic trends in bladder cancer: a systematic analysis","volume":"111","author":"Zhang","year":"2025","journal-title":"Int J Surg"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03469-5","article-title":"Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study","volume":"72","author":"Santoni","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/cimb47040278","article-title":"Cytokine therapy in bladder cancer: mechanisms, efficacy, and future prospects","volume":"47","author":"Oyler","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.urolonc.2022.05.013","article-title":"Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non-muscle invasive bladder cancer: Invited review for special issue \u201cSeminar: Treatment Advances and Molecular Biology Insights in Urothelial Carcinoma","volume":"41","author":"Chu","year":"2023","journal-title":"Urol Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103972","article-title":"Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial","volume":"9","author":"Rosenberg","year":"2024","journal-title":"ESMO Open"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.04.016","article-title":"Patient-reported outcomes from JAVELIN bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma","volume":"83","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110393","article-title":"Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect","volume":"129","author":"Han","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6768","article-title":"Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer","volume":"12","author":"Hannouneh","year":"2023","journal-title":"Cancer Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s1470-2045(23)00540-5","article-title":"Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study","volume":"25","author":"Grande","year":"2024","journal-title":"Lancet Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-2158","article-title":"Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"16325","DOI":"10.3390\/ijms242216325","article-title":"CRISPR\/cas9-mediated genome editing in cancer therapy","volume":"24","author":"Ding","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B111","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3390\/diagnostics11020306","article-title":"Urinary cell-free DNA in bladder cancer detection","volume":"11","author":"Tse","year":"2021","journal-title":"Diagn (Basel)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2017.11.025","article-title":"Evaluation of urinary DNA methylation as a marker for recurrent bladder cancer: A 2-center prospective study","volume":"113","author":"Shindo","year":"2018","journal-title":"Urology"},{"key":"B113","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/path.6166","article-title":"Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial","volume":"261","author":"Zang","year":"2023","journal-title":"J Pathol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.07.001","article-title":"Association of tumor-informed circulating tumor DNA detectability before and after radical cystectomy with disease-free survival in patients with bladder cancer","volume":"8","author":"Sfakianos","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.03.002","article-title":"Longitudinal tumor-informed circulating tumor DNA status predicts disease upstaging and poor prognosis for patients undergoing radical cystectomy","volume":"7","author":"Ben-David","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2021.100100","article-title":"Intravesical drug delivery approaches for improved therapy of urinary bladder diseases","volume":"3","author":"Palugan","year":"2021","journal-title":"Int J Pharm X"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/kjm2.12845","article-title":"The value of urinary exosomal microRNA-21 in the early diagnosis and prognosis of bladder cancer","volume":"40","author":"Yang","year":"2024","journal-title":"Kaohsiung J Med Sci"},{"key":"B118","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/cad.0000000000000499","article-title":"Activation of a c-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cells","volume":"28","author":"Huang","year":"2017","journal-title":"Anticancer Drugs"},{"key":"B119","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.eururo.2025.03.018","article-title":"Use of the xpert bladder cancer monitor urinary biomarker test for guiding cystoscopy in high-grade non-muscle-invasive bladder cancer: results from the randomized controlled daBlaCa-15 trial","volume":"88","author":"Dreyer","year":"2025","journal-title":"Eur Urol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(10)70296-5","article-title":"A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment","volume":"12","author":"Smith","year":"2011","journal-title":"Lancet Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.04.061","article-title":"Prediction of lymph node metastasis in patients with bladder cancer using whole transcriptome gene expression signatures","volume":"196","author":"Seiler","year":"2016","journal-title":"J Urol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.3390\/cancers15061856","article-title":"New approaches to targeting epigenetic regulation in bladder cancer","volume":"15","author":"Thompson","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-012-3110-4","article-title":"Siliconchiptechnology-based MMP-7 analysis in urine: an option for preoperative identification of lymph node metastasis in bladder cancer","volume":"52","author":"J\u00e4ger","year":"2013","journal-title":"Urol A"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-1510","article-title":"A radiomics nomogram for the preoperative prediction of lymph node metastasis in bladder cancer","volume":"23","author":"Wu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ebiom.2018.07.029","article-title":"Development and validation of an MRI-based radiomics signature for the preoperative prediction of lymph node metastasis in bladder cancer","volume":"34","author":"Wu","year":"2018","journal-title":"EBioMedicine"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2021.02.004","article-title":"Diagnosis and staging of bladder cancer","volume":"35","author":"Ahmadi","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"B129","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/cancers14030487","article-title":"DNA methylome changes of muscle- and neuronal-related processes precede bladder cancer invasiveness","volume":"14","author":"Bo\u0161kovi\u0107","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-24-0012","article-title":"Evaluating debio 1347 in patients with FGFR fusion-positive advanced solid tumors from the FUZE multicenter, open-label, phase II basket trial","volume":"30","author":"Grivas","year":"2024","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1670574\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T05:12:44Z","timestamp":1765170764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1670574\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":130,"alternative-id":["10.3389\/fonc.2025.1670574"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1670574","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"article-number":"1670574"}}